A unique product for the Pathology and Healthcare industry
In response to the Carter review all Pathology departments are charged with identifying significant savings to contribute towards a national estimate of £500 million. Not only is this a challenging time for Pathology but it also means the development of effective and standard tools to achieve this target within a relatively short timeframe is long overdue. Historically, some Pathology departments have built in-house programmes to cost tests but there is no published evidence to indicate their reliability or their effectiveness outside the site they are implemented. Without a market-driven standardised technique for costing Pathology the reliability of Pathology costing is still questionable.